VIA DBM™ PUTTY

VIA DBM PUTTY™

DEMINERALIZED BONE MATRIX PUTTY

VIA DBM Putty™ was engineered for superior performance.[1] The graft does not adhere to gloves, yet maintains its placement in the surgical environment. Osteoinductivity of sterile final product is assessed in vivo. In this challenging model, every lot tested to date has consistently demonstrated an osteoinductive response.

- Equivalent to iliac crest autograft proven in a preclinical spinal fusion model[2]
- Assured osteoinductivity via validated processing
- Cohesive handling that resists irrigation due to robust biocompatible carrier
- Patient safety assured through terminal sterilization and viral inactivation

INDICATIONS FOR USE

- Indicated for use as a bone void filler for voids or gaps in the extremities and pelvis that are not intrinsic to the stability of the bony structure.
- Indicated for treatment of surgically created osseous defects or osseous defects from traumatic injury to the bone.
- Can be used as follows:
  - Extremities
  - Posterolateral spine
  - Pelvis

ORDERING INFORMATION

CODE	DESCRIPTION	SIZE
DBM001	VIA DBM Putty™	1.0cc
DBM002	VIA DBM Putty™	2.0cc
DBM005	VIA DBM Putty™	5.0cc
DBM010	VIA DBM Putty™	10.0cc

VIA DBM PLUS HISTOLOGY IN AN ANIMAL MODEL INDICATING ROBUST OSTEOINDUCTIVITY[2]



Adjacent bone formation 12 weeks postoperatively at 10X



Osteoblastic activity at 10X



New osteoid formation at 20X

Osteoblastic organization and activity with cellular marrow components present at 20X

VIADBM™ PUTTY



SAFE AND TRUSTED PARTNER

Our portfolio of allografts and other signature VIVEX solutions include viable bone matrices; demineralized bone matrices, such as cortical and cancellous bone in strips, sponges, fibers, and putties; amnion; dermis; and intervertebral disc tissue allografts. During the more than 50 years of safe and effective operations, VIVEX has safely delivered over 2 million allografts with no disease transmission throughout the US and eighteen countries worldwide.

50 years of regeneration

1970 — University of Miami Tissue Bank formed by Theodore I. Malinin, MD

1972 — Frozen and freeze-dried allografts routinely supplied to surgeons for reconstructive procedures of the axial skeleton, filling of smaller defects of bone for arthrodesis

1974 — First transplant of a massive intercalary allograft prepared by the tissue bank

1978 — First transplant of a massive osteoarticular allograft prepared by the tissue bank

1988 — Acquired new facilities, allowing for design of a dedicated operating suite used exclusively for the excision of tissues for transplantation

2011 — Tissue bank relocated to new state-of-the-art facilities to accommodate a diverse group of biotech and life science organizations

2014 — VIVEX acquires University of Miami Tissue Bank and continues to focus on new product development, research, and innovation

Launched
VIA Graft
CYGNUS Solo

2015 — Launched
VIA Graft Moldable
VIA Form
VIA Form Moldable
ALLOGEN
CYGNUS Max

2016 — Completed first VIA Graft clinical study

Launched CYGNUS Matrix

2017 — VIA Graft study published in IJSS

2018 — Transitioned to next-gen DMSO-free cryoprotectant

Launched
ALLOGEN Liquid

2019 — Distributed 50k VIA Units

2020 — VIA Disc Limited Release

Move into new state-of-the-art facility

2021 — Launched
VIAGENEX
VIA Mend
VIA DBM

1. Data on file at Xtant Medical.

2. Kiely, P.D. et al., (2014) Evaluation of a new formulation of demineralized bone matrix putty in a rabbit posterolateral spinal fusion model. The Spine Journal. September 14(9): 2155-2163

VIVEX BIOLOGICS

2430 NW 116th Street, Miami, FL 33167
(888) 684-7783 | vivex.com | customercare@vivex.com

MKG-OFT-15 Rev. 01